Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor.

× No keyword cloud information.

10 in total

1. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

Authors: Philip M Grant; Camlin Tierney; Chakra Budhathoki; Eric S Daar; Paul E Sax; Ann C Collier; Margaret A Fischl; Andrew R Zolopa; Maya Balamane; David Katzenstein
Journal: HIV Clin Trials Date: 2013 Nov-Dec

2. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.

Authors: Marco Petrella; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Bluma G Brenner; Mark A Wainberg
Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191

3. Playing well with others! Initiating and sustaining successful collaborations between industry, academia and government.

Authors: Craig J Thomas; John C McKew
Journal: Curr Top Med Chem Date: 2014 Impact factor: 3.295

4. Disorder in clotting pattern after antiretroviral treatment with emtricitabine in an HIV-positive haemophiliac patient.

Authors: Antonio Liras
Journal: Clin Drug Investig Date: 2007 Impact factor: 2.859

5. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.

Authors: Kirsten M Stray; Rujuta A Bam; Gabriel Birkus; Jia Hao; Eve-Irene Lepist; Stephen R Yant; Adrian S Ray; Tomas Cihlar
Journal: Antimicrob Agents Chemother Date: 2013-07-29 Impact factor: 5.191

6. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.

Authors: Anna S F Lok; Fabien Zoulim; Stephen Locarnini; Alessandra Mangia; Grazia Niro; Hilde Decraemer; Geert Maertens; Frank Hulstaert; Karen De Vreese; Erwin Sablon
Journal: J Clin Microbiol Date: 2002-10 Impact factor: 5.948

7. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.

Authors: Joy Y Feng; Eisuke Murakami; Suzana M Zorca; Allison A Johnson; Kenneth A Johnson; Raymond F Schinazi; Phillip A Furman; Karen S Anderson
Journal: Antimicrob Agents Chemother Date: 2004-04 Impact factor: 5.191

Review 8. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

Authors: Michele W Tang; Phyllis J Kanki; Robert W Shafer
Journal: Clin Infect Dis Date: 2012-03 Impact factor: 9.079

9. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro.

Authors: Rui-Rui Wang; Qing-Hua Yang; Rong-Hua Luo; You-Mei Peng; Shao-Xing Dai; Xing-Jie Zhang; Huan Chen; Xue-Qing Cui; Ya-Juan Liu; Jing-Fei Huang; Jun-Biao Chang; Yong-Tang Zheng
Journal: PLoS One Date: 2014-08-21 Impact factor: 3.240

10. New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.

Authors: Nimish Patel; Christopher D Miller
Journal: HIV AIDS (Auckl) Date: 2012-04-27

10 in total